SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esperas Pharma Inc.
NuCana plc
Virginia Commonwealth University
University of Alabama at Birmingham
Case Comprehensive Cancer Center
University of Kansas Medical Center
M.D. Anderson Cancer Center
Essen Biotech
Augusta University
University Hospital, Linkoeping
Brown University
Sadat City University
H. Lee Moffitt Cancer Center and Research Institute
University of Arkansas
Roswell Park Cancer Institute
University of Louisville
Xiangya Hospital of Central South University
Jonsson Comprehensive Cancer Center
Brown University
University of Leicester
Stanford University
National Taiwan University Hospital
Swiss Cancer Institute
Icahn School of Medicine at Mount Sinai
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
Xuanwu Hospital, Beijing
Medical University of South Carolina
Stanford University
University of Southern California
University of British Columbia
First Affiliated Hospital of Chengdu Medical College
University of California, Irvine
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Medical University of Vienna
University Hospital, Basel, Switzerland
University of Utah
University of Southern California
University of British Columbia
Rutgers, The State University of New Jersey
University of Chicago
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
The University of Texas Health Science Center at San Antonio